CN100358582C - Early senile dementia alpha beta starch spot imaging agent - Google Patents
Early senile dementia alpha beta starch spot imaging agent Download PDFInfo
- Publication number
- CN100358582C CN100358582C CNB2005100567889A CN200510056788A CN100358582C CN 100358582 C CN100358582 C CN 100358582C CN B2005100567889 A CNB2005100567889 A CN B2005100567889A CN 200510056788 A CN200510056788 A CN 200510056788A CN 100358582 C CN100358582 C CN 100358582C
- Authority
- CN
- China
- Prior art keywords
- alpha beta
- imaging agent
- product
- post
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention discloses a novel alpha beta-starch plaque imaging agent for presinal dementia, which has the following structure formula: R4-R2-C=N-R1-R3, wherein the R1 and the R2 represent aromatic rings; the R3 is an N-methyl group or an N, or an N-dimethyl group or a methoxyl group, which is positioned on a para position or an ortho position or a meta position of the aromatic ring on one side; the R4 is a group with radioactive nuclein, which is positioned on the para position or the ortho position or the meta position of the aromatic ring on the other side; the positions of the R3 and the R4 can be exchanged. The alpha beta-starch plaque imaging agent is mainly used for raster display for alpha beta-starch plaque of the intravital central nerve, and diagnosis and evaluation for presinal dementia. The affinity constant of the chemical compound of the present invention and alpha beta (1 to 40) aggregation is very high, which can reach n M grade.
Description
Technical field
The present invention relates to a kind of medical developer that contains radioactive substance, be specially a kind of early senile dementia alpha beta starch spot imaging agent.
Background technology
One of main neuropathological feature of alzheimer disease (being called for short AD) patient is the senile plaque accumulation, its Main Ingredients and Appearance is amyloid-beta (being called for short A β), A β is one of two macromole marks of AD, also is the goldstandard of clinical postmortem or biopsy diagnosis AD.The stain that pathology detect A β has: (Congo Red, CR), thioflavin-T (Thioflavin-T), thioflavin-S, Chrysamine G (CG) and X-34 etc., these reagent have very high affinity at external and A β to Congo red.If use the radioisotope labeling mentioned reagent, and can effectively break through blood brain barrier (be called for short BBB) and enter brain, just can adopt SPECT or PET technology, carry out senile plaque distribution and quantitative in AD patient's brain in body, visual detection, can improve the early diagnostic rate of AD and differentiate accuracy rate, and can to patient AD by stages, be that the therapeutic scheme (as reducing the A β etc. that A β precursor protein generated, suppressed the generation of A β and gathers, removes generation) of target spot and the research of medicine etc. provide effective evaluation methodology at A β.
The advantage of nuclear medicine image is to have the dyeing of unique pathology or biochemical bonded reagent is made developer with radioisotope labeling, helps disease at body, noninvasive specific diagnosis.Directly,, be not easy to penetrate BBB owing to divide subclass big with radioisotope labeling CG class.In recent years reported in literature the improvement labels of several classes to above chemical compound, obtained certain achievement at zoopery, external autography and preliminary clinicing aspect.
The first kind is
18F-FDDNP, it is that one roughly the same ibuprofen, naproxen chemical constitution are similar, the competition binding site is different from the chemical compound (Agdeppa ED, Neuroscience 117 (2003) 723-730) of Congo red (CG) and thioflavin (Thioflavine T) when combining with the A beta plaque.
FDDNP DDNP structural formula
This chemical compound has been used for the diagnosis of clinical AD, patient's AD at present
18The F-FDDNP video picture is concentrated and the low metabolism position consistency of FDG, and the normal control group does not have and concentrates.This developer deficiency is that the injection back is slower from the removing in normal brain activity district.
The second class developer is benzothiophene kind and derivant thereof, is very similar compounds of a class and thioflavin-T (Thioflavin-T) chemical constitution,
125I or
18F,
11The BAT compounds and the A β of C labelling have good affinity, wherein
11The Ki=10nM of the BAT of C labelling (Mathis CA, Bioorg ﹠amp; Medic Chemlett, 2002,12:295-298),
11C-6-0H-BAT is at the clinical preliminary identification that obtains.The characteristics of this compounds are that two aromatic rings of connection are First Five-Year Plan unit's heterocycle, wherein have one for two keys (structural formula as follows), by two keys electron cloud on the aromatic ring of both sides are interacted.Remove soon behind such compound injection of positron radionuclide labelling, the video picture of A beta plaque is clear, is suitable for the diagnosis of clinical early stage AD.But the chemical compound normal brain activity of iodine labeling is removed slow, in order to improve from the removing in normal brain activity district, change S into O, become IBOX, though obviously bring up to 0.8nM with the affinity of A β 1-40, the chemical compound of iodine labeling is still removed slow from the normal brain activity district, the 2min/60min ratio is 1 (Zhuang ZP, Nucl Med Biol, 2001,887-894).Change O into N, increase a pair of key simultaneously, become IMPY, though drop to 15nM with combining of A β, but obviously having increased normal brain activity and blood behind the iodine labeling removes, the 2min/60min ratio is 12, increased target this than (Kung MP, 2002, Brain Research, 2002,202-210), its clinical value needs further checking.
Benzothiazoles IBOX class IMPY class
The 3rd class developer is the simplification of second class.Between two aromatic rings, the simplest is directly to be connected into biphenyl, owing to lose the effect of two keys, influence between two aromatic rings and diminish, and A β affinity decline (between 17~100nM).Further modify the key between two phenyl ring, make the increasing that influences each other between the aromatic rings, connect with five-membered ring, and the one-tenth fluorenes (Lee CW, Nucl Med Biol, 2003:573-580).As long as iodine labeling in place, can reach the Ki (0.92nM) higher with A β, but the fluorenes class of iodine labeling is unhappy from the removing of normal brain activity district, and the 2min/60min ratio is 1.57.
Benzene dienes fluorenes class biphenyl class
In order to improve the removing in normal brain activity district, keeping simultaneously with A β has higher affinity, use carbon-carbon double bond between two aromatic rings, influencing each other between the increase aromatic ring, noval chemical compound be the benzene diene (Kung HF, J AmChem Soc, 2001,123:12740-41).Keep higher level with the affinity costant of A β, reach 1.2nM.With
11The benzene diene of C labelling is 3.8 at normal brain activity district 60min/2min ratio, and external autography shows,
11A β has obvious the combination in the benzene dienes of C labelling and the model mouse brain, target this than higher (Ono M, Nucl MedBiol, 2003,30:565).The benzene diene is a class CNS speckle more likely developer.
Summary of the invention
The invention provides a kind of radiolabeled Schiff bases early senile dementia alpha beta starch spot imaging agent, this developer is used for the video picture of the nervus centralis A β-starch speckle of live body, can diagnose and estimate dementia senilis.
The general structure of this radiolabeled Schiff bases early senile dementia alpha beta starch spot imaging agent is as follows:
R4-R2-C=N-R1-R3
R1 wherein, R2 is expressed as phenyl ring, naphthols or biphenyl; R3 is in the para-position of a side aromatic ring, is N-methyl or N, N-dimethyl or methoxyl group; R4 is in the para-position or an ortho position or a position of opposite side aromatic ring, for-O
11CH
3,-NH
11CH
3,-
18F or-
125The I group; R3 and R4 position are interchangeable.
Aforesaid radiolabeled Schiff bases early senile dementia alpha beta starch spot imaging agent, wherein when R3 was methoxyl group, carbon can be radioactive carbon-11 on this group.
The three kinds of chemical compounds belonging to above-mentioned developer and the affinity costant Ki of starch protein A β (1-40) aggregation are measured, measure used A β (1-40) aggregation and
125I-TZDM, its measuring method is as follows:
Get A β (1-40) aggregation (final analysis concentration is 10-50nM) of 50 μ L, add 50 μ L's
125I-TZDM (100,000 countings/min), add the competitor of 50 μ L, and final volume is diluted to 1mL.Place after 3 hours under the room temperature and separate with cell harvestor, diffusion barrier is a Whatman GF/B filter membrane, and with counting on γ-counter measures film, the Ki result who calculates competitor is as follows:
Compound K i (nM)
This shows that the affinity costant of these three chemical compounds and A β (1-40) aggregation is very high, reaches the nM level, all can become the diagnostic agent and the treatment therapeutic evaluation agent of presenile dementia.
The specific embodiment
Embodiment one
11The synthesizing hydroxyl Schiff bases developer of C labelling
Synthesizing of precursor:
Take by weighing 1.8g to N, the N dimethylbenzaldehyde is dissolved in the 30ml dehydrated alcohol, adds the para-aminophenol of 1.5g again, refluxes 3 hours.A large amount of flaxen precipitations are arranged, and filtration, drying obtain the flaxen crystallization of 2.77g, and productive rate is 89%.H?NMR(500MHZ,DMSO,δ):3.0(6H),6.77(4H),7.10(2H),7.71(2H),8.39(1H),9.3(1H)。
Radioactive label:
Take by weighing 1mg to N, N dimethyl, to hydroxyl Schiff alkali is dissolved among the 0.4mlDMSO, adds 2N NaOH 10 μ L.In this solution, feed
11CH
3I separates with partly preparing HPLC, and detached dowel is the C-18 post, and mobile phase is water: acetonitrile (710: 290 V/V), flow velocity 1mL/min, wavelength 280nm.The Rt of product is 5.5min, collects the product peak.Or, in label, add 10ml water with the separation of Sep-Pak C-18 post, and cross the C-18 post, the water flushing washes product get off with 1ml ethanol.Labeling effciency is 73%.
Embodiment two
11Hydroxyl Schiff bases developer is synthetic between the C labelling
Synthesizing of precursor:
Take by weighing 1.8g to N, the N dimethylbenzaldehyde is dissolved in the 30ml dehydrated alcohol, adds the 3-amino-phenol of 1.5g again, refluxes 3 hours.A large amount of flaxen precipitations are arranged, and filtration, drying obtain the flaxen crystallization of 2.5g, and productive rate is 81%.H?NMR(500MHZ,DMSO,δ):3.0(6H),5.06(1H),6.62(2H),6.7(2H),6.8(1H),7.10(1H),7.44(2H),8.9(1H)。
Radioactive label:
Take by weighing 1mg to N, N dimethyl, a hydroxyl Schiff alkali are dissolved among the 0.4mlDMSO, add 2N NaOH 10 μ L.In this solution, feed
11CH
3I separates with partly preparing HPLC, and detached dowel is the C-18 post, and mobile phase is water: acetonitrile (710: 290 V/V), flow velocity 1mL/min, wavelength 280nm.The Rt of product is 5.5min, collects the product peak.Or, in label, add 10ml water with the separation of Sep-Pak C-18 post, and cross the C-18 post, the water flushing washes product get off with 1ml ethanol.Labeling effciency is 70%.
Embodiment three
11Synthesizing of the naphthols Schiff bases developer of C labelling
Synthesizing of precursor:
Take by weighing 1.8g to N, the N dimethylbenzaldehyde is dissolved in the 30ml dehydrated alcohol, adds 5-amino-1-naphthols of 2.15g again, refluxes 3 hours.A large amount of brown precipitations are arranged, filtration, drying, the crystallization that the 1.7g that obtains is brown, productive rate is 50%.H?NMR(500MHZ,DMSO,δ):3.0(6H),5.06(1H),6.6(3H),7.2(1H),7.3(2H),7.4(3H),8.1(H),9.1(1H)。
Radioactive label:
Take by weighing 1mg to N, N dimethyl, naphthols Schiff alkali are dissolved among the 0.4mlDMSO, add 2NNaOH 10 μ L.In this solution, feed
11CH
3I separates with partly preparing HPLC, and detached dowel is the C-18 post, and mobile phase is water: acetonitrile (710: 290 V/V), flow velocity 1mL/min, wavelength 280nm.The Rt of product is 5.5min, collects the product peak.Or, in label, add 10ml water with the separation of Sep-Pak C-18 post, and cross the C-18 post, the water flushing washes product get off with 1ml ethanol.Labeling effciency is 75%.
Embodiment four
11Synthesizing of the biphenyl Schiff bases developer of C labelling
Synthesizing of precursor:
Take by weighing 1.8g to N, the N dimethylbenzaldehyde is dissolved in the 30ml dehydrated alcohol, adds 2-amido-4-benzene-phenol of 2.47g again, refluxes 3 hours.The precipitation that a large amount of whites are arranged, filtration, drying, the crystallization of the 1.37g white that obtains, productive rate is 36%.HNMR(500MHZ,DMSO,δ):3.0(6H),5.06(1H),6.62(2H),6.8(H),7.22(1H),7.3(2H),7.32(2H),7.44(2H),7.48(2H),8.8(1H)。
Radioactive label:
Take by weighing 1mg to N, N dimethyl diphenyl Schiff alkali is dissolved among the 0.4mlDMSO, adds 2N NaOH10 μ L.In this solution, feed
11CH
3I separates with partly preparing HPLC, and detached dowel is the C-18 post, and mobile phase is water: acetonitrile (710: 290 V/V), flow velocity 1mL/min, wavelength 280nm.The Rt of product is 5.5min, collects the product peak.Or, in label, add 10ml water with the separation of Sep-Pak C-18 post, and cross the C-18 post, the water flushing washes product get off with 1ml ethanol.Labeling effciency is 23%.
Embodiment five
11Synthetic (the N-C place-exchange) to hydroxyl Schiff bases developer of C labelling
Synthesizing of precursor:
Take by weighing 1.2g to N, the N dimethylaniline is dissolved in the 30ml dehydrated alcohol, adds the para-aminophenol of 1.2g again, refluxes 3 hours.A large amount of flaxen precipitations are arranged, and filtration, drying obtain the flaxen crystallization of 2.1g, and productive rate is 87%.H?NMR(500MHZ,DMSO,δ):3.0(6H),5.0(H),6.60(2H),6.76(2H),7.10(2H),7.52(2H),9.2(1H)。
Radioactive label:
Take by weighing 1mg to N, N dimethyl, to hydroxyl Schiff alkali is dissolved among the 0.4mlDMSO, adds 2N NaOH 10 μ L.In this solution, feed
11CH
3I separates with partly preparing HPLC, and detached dowel is the C-18 post, and mobile phase is water: acetonitrile (710: 290 V/V), flow velocity 1mL/min, wavelength 280nm.The Rt of product is 5.5min, collects the product peak.Or, in label, add 10ml water with the separation of Sep-Pak C-18 post, and cross the C-18 post, the water flushing washes product get off with 1ml ethanol.Labeling effciency is 75%.
Embodiment six
11The synthesizing amido Schiff bases developer of C labelling
Synthesizing of precursor:
Take by weighing the p-phenylenediamine (PPD) of 1.0g, be dissolved in the 15ml dehydrated alcohol, reflux.Slowly drip the N to 1.2g in solution, N dimethylbenzaldehyde (alcoholic solution) adds in 90min, refluxes 2 hours again.A large amount of xanchromatic precipitations are arranged, and filtration, drying obtain the flaxen thick product of 0.6g.Separate with lamellae, ethyl acetate and normal hexane are made mobile phase, obtain the 0.5g product.H?NMR(500MHZ,DMSO,δ):3.0(6H),4.2(2H),6.5(2H),6.77(2H),7.2(2H),7.44(2H),9.3(1H)。
Radioactive label:
Take by weighing 1mg to N, N dimethyl, to amido Schiff alkali is dissolved among the 0.4mlDMSO, adds 2N NaOH 10 μ L.In this solution, feed
11CH
3I separates with partly preparing HPLC, and detached dowel is the C-18 post, and mobile phase is water: and acetonitrile (71O: 290V/V), flow velocity 1mL/min, wavelength 280nm.The Rt of product is 5.5min, collects the product peak.Or, in label, add 10ml water with the separation of Sep-Pak C-18 post, and cross the C-18 post, the water flushing washes product get off with 1ml ethanol.Labeling effciency is 61%.
Embodiment seven
11The methoxyl group of C labelling is to synthesizing of amido Schiff bases developer
Synthesizing of precursor:
Take by weighing the p-phenylenediamine (PPD) of 1.0g, be dissolved in the 15ml dehydrated alcohol, reflux.In solution, slowly drip P-methoxybenzal-dehyde (alcoholic solution), in 90min, add, refluxed again 2 hours 1.1g.Xanchromatic precipitation is arranged, and filtration, drying obtain the xanchromatic thick product of 0.5g.Separate with lamellae, ethyl acetate and normal hexane are made mobile phase, obtain the 0.45g product.H?NMR(500MHZ,DMSO,δ):3.7(3H),4.0(2H),6.5(2H),6.80(2H),7.0(2H),7.51(2H),9.3(1H)。
Radioactive label:
The methoxyl group that takes by weighing 1mg is dissolved among the 0.4mlDMSO amido Schiff alkali, adds 2N NaOH10 μ L.In this solution, feed
11CH
3I separates with partly preparing HPLC, and detached dowel is the C-18 post, and mobile phase is water: acetonitrile (710: 290 V/V), flow velocity 1mL/min, wavelength 280nm.The Rt of product is 5.5min, collects the product peak.Or, in label, add 10ml water with the separation of Sep-Pak C-18 post, and cross the C-18 post, the water flushing washes product get off with 1ml ethanol.Labeling effciency is 58%.
Carbon on this developer methoxyl group can be radioactive carbon-11, is used for video picture simultaneously.
Embodiment eight
18Synthesizing of the para-position Schiff bases developer of F labelling
Synthesizing of precursor:
Take by weighing 1.19g to N, the N dimethylbenzaldehyde is dissolved in the 30ml dehydrated alcohol, adds the paranitroanilinum of 1.1g again, refluxes 3 hours.A large amount of flaxen precipitations are arranged, filtration, drying, ethyl alcohol recrystallization obtains the 1.35g product, and productive rate is 65%.H?NMR(500MHZ,DMSO,δ):3.05(6H),6.60(2H),6.80(2H),7.69(2H),7.95(2H),9.67(1H)。
Radioactive label:
Accelerator-produced
18F
-Ion after QMA absorption by the K2.2.2/K of 1.5ml
2CO
3The acetonitrile solution eluting is gone into reaction tube, the DMSO solution that after secondary removes acetonitrile, adds the nitro precursor that contains 2mg-3mg, behind reaction 10min under 130 ℃, cooling is after adding 10ml water and residue are mixed, and the startup negative pressure enters waste liquid bottle with liquid in the reaction bulb through the C-18 post.Thick product is attracted on the C-18 post.Divide three times 15ml water to be sucked waste liquid bottle through negative pressure, with K2.2.2 and the DMSO eluting that remains on the C-18.Again threeway is switched to the product receiving flask, add 1ml ethanol receiving flask is gone in the product drip washing on the C-18 post.Add an amount of normal saline,, obtain after aseptic filter membrane
18F-N, N dimethyl, to fluorine Schiff alkali.Mark rate is 25%.
Embodiment nine
18Synthesizing of the ortho position Schiff bases developer of F labelling
Synthesizing of precursor:
Take by weighing 1.19g to N, the N dimethylbenzaldehyde is dissolved in the 30ml dehydrated alcohol, adds the ortho-nitraniline of 1.1g again, refluxes 3 hours.A large amount of flaxen precipitations are arranged, filtration, drying, ethyl alcohol recrystallization obtains the 1.12g product, and productive rate is 42%.H?NMR(500MHZ,DMSO,δ):3.0(6H),6.62(2H),7.44(2H),7.52(2H),7.7(2H),8.21(H),8.39(1H)。
Radioactive label:
Accelerator-produced
18F
-Ion after QMA absorption by the K2.2.2/K of 1.5ml
2CO
3The acetonitrile solution eluting is gone into reaction tube, after secondary removes acetonitrile, add contain 2mg-3mg between the DMSO solution of nitro precursor, behind reaction 10min under 130 ℃, cooling is after adding 10ml water and residue are mixed, and the startup negative pressure enters waste liquid bottle with liquid in the reaction bulb through the C-18 post.Thick product is attracted on the C-18 post.Divide three times 15ml water to be sucked waste liquid bottle through negative pressure, with K2.2.2 and the DMSO eluting that remains on the C-18.Again threeway is switched to the product receiving flask, add 1ml ethanol receiving flask is gone in the product drip washing on the C-18 post.Add an amount of normal saline,, obtain after aseptic filter membrane
18F-N, N dimethyl, adjacent fluorine Schiff alkali.Mark rate is 18%.
Embodiment ten
125Synthesizing of the Schiff bases developer of I labelling
Synthesizing of precursor:
Take by weighing 298mg to N, the N dimethylbenzaldehyde is dissolved in the 30ml dehydrated alcohol, adds the para-bromoaniline of 344mg again, refluxes 3 hours.Remove ethanol, filtration, drying, ethyl alcohol recrystallization obtains the 0.4g product, productive rate 65%.Fusing point: 136 ℃, H NMR (500MHZ, DMSO, δ): 2.92 (6H), 6.41 (2H), 7.05 (2H), 7.6 (2H), 9.57 (H).
Get 52mg to bromine Schiff alkali, with the Pd (Ph of 20mg
3P)
4Be dissolved in the 12ml triethylamine solution, 90 ℃ of reactions 12 hours.Desolventize,, obtain the precursor of 20mg with TLC method purification.
Radioactive label:
Prepare the Xi Dingji precursor alcoholic solution of 50 μ g/50 μ L, add an amount of Na
125I solution is regulated PH, and room temperature is reaction 10min down, adds the NaHSO of 100 μ L
4Neutralization.Directly use ethyl acetate extraction, dry up, the dissolving of 10% ethanol normal saline solution.
Claims (2)
1. radiolabeled Schiff bases early senile dementia alpha beta starch spot imaging agent, its general structure is as follows:
R4-R2-C=N-R1-R3
R1 wherein, R2 is expressed as phenyl ring, naphthols or biphenyl; R3 is in the para-position of a side aromatic ring, is N-methyl or N, N-dimethyl or methoxyl group; R4 is in the para-position or an ortho position or a position of opposite side aromatic ring, for-O
11CH
3,-NH
11CH
3,-
18F or-
125The I group; R3 and R4 position are interchangeable.
2. radiolabeled Schiff bases early senile dementia alpha beta starch spot imaging agent as claimed in claim 1, it is characterized in that: when R3 was methoxyl group, carbon can be radioactive carbon-11 on this group.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100567889A CN100358582C (en) | 2005-03-25 | 2005-03-25 | Early senile dementia alpha beta starch spot imaging agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100567889A CN100358582C (en) | 2005-03-25 | 2005-03-25 | Early senile dementia alpha beta starch spot imaging agent |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1686569A CN1686569A (en) | 2005-10-26 |
CN100358582C true CN100358582C (en) | 2008-01-02 |
Family
ID=35304611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100567889A Expired - Fee Related CN100358582C (en) | 2005-03-25 | 2005-03-25 | Early senile dementia alpha beta starch spot imaging agent |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100358582C (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104178132B (en) * | 2014-07-30 | 2017-01-25 | 四川大学 | Fluorescent compound and application thereof in medicine |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1266884A1 (en) * | 2000-03-22 | 2002-12-18 | BF Research Institute, Inc. | Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same |
-
2005
- 2005-03-25 CN CNB2005100567889A patent/CN100358582C/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1266884A1 (en) * | 2000-03-22 | 2002-12-18 | BF Research Institute, Inc. | Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same |
Also Published As
Publication number | Publication date |
---|---|
CN1686569A (en) | 2005-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2620177T3 (en) | Imaging agents and their use for in vivo diagnosis of neurodegenerative diseases, particularly Alzheimer's disease and derived diseases | |
Ono et al. | Novel chalcones as probes for in vivo imaging of β-amyloid plaques in Alzheimer’s brains | |
MX2012009174A (en) | Methods and apparatus for synthesizing imaging agents, and intermediates thereof. | |
US20090041663A1 (en) | Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors | |
NO330176B1 (en) | Amyloid Binding Compounds, Methods of Preparation and Use, Pharmaceutical Composition for In Vivo Imaging and Use thereof | |
CN104159890A (en) | Compositions, methods, and systems for the synthesis and use of imaging agents | |
JP2021513979A (en) | Chemical conjugates of Evans blue derivatives and their use as radiation therapy and contrast agents to target prostate cancer | |
Wu et al. | Dibenzothiazoles as novel amyloid-imaging agents | |
Cui et al. | Synthesis and evaluation of novel benzothiazole derivatives based on the bithiophene structure as potential radiotracers for β-amyloid plaques in Alzheimer’s disease | |
CN102180780A (en) | Indenone derivative and applications thereof as developing agent and aggregation inhibitor of amyloid protein deposit and neurofibrillary tangle | |
Serdons et al. | Synthesis of 18F-labelled 2-(4′-fluorophenyl)-1, 3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C] PIB | |
Lee et al. | Dimethylamino-fluorenes: ligands for detecting β-amyloid plaques in the brain | |
Fuchigami et al. | Synthesis and evaluation of ethyleneoxylated and allyloxylated chalcone derivatives for imaging of amyloid β plaques by SPECT | |
Ono et al. | 18F-labeled flavones for in vivo imaging of β-amyloid plaques in Alzheimer’s brains | |
JP6840666B2 (en) | New anthranilic acid derivative | |
EP2198040B1 (en) | In vivo imaging of myelin | |
US20090123373A1 (en) | Amyloid-imaging agents | |
US20140336503A1 (en) | Radiolabeled biomarkers for osteoclast activation and related methods thereof | |
CN102557969A (en) | Cyclic ketone derivatives and applications thereof as developers and aggregation inhibitors of amyloid protein sediments and neurofibrillary tangles | |
CN100358582C (en) | Early senile dementia alpha beta starch spot imaging agent | |
EP2711026A1 (en) | Radioactive fluorine-labeled quinoxaline compound | |
CN101020698A (en) | Benzothiazole aniline compound marked with Tc-99m and its prepn process and application | |
CN102432529B (en) | Preparation method of styryl pyridine disulfide dinitrogen derivative | |
Watanabe et al. | Synthesis and biological evaluation of radioiodinated 2, 5-diphenyl-1, 3, 4-oxadiazoles for detecting β-amyloid plaques in the brain | |
CN101888992A (en) | Contrast medium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |